Let’s Make A Difference!

Apple-smallWelcome to Theradym’s blog! Theradym’s mission is to integrate technology and therapeutics to improve therapeutic outcomes. We’re here to highlight issues compromising patient outcomes and to reduce the healthcare burden on our economy.

We do this by exploring therapeutics, making discovery and providing direction to improve patient outcomes. Using comparative effectiveness research, we enable better health care decisions. This improves patient outcomes and recovery. In particular, we develop the evidence needed for improved cost-benefit decisions. Today there is limited ability to determine the benefit of therapeutic applications and their downstream impacts.

We will cover a number of issues and therapeutic interventions on this blog. Chronic pain effects one in three Americans and half are inadequately treated. Since it touches virtually every member of our society, we will discuss chronic pain first. Topics we’ll cover include the Opioid Conundrum, the topical treatment of pain, micro-current therapy, neutraceuticals, and other treatment strategies – all focused on improving patient management and recovery while reducing costs and negative physiological adverse events.

Working together, let’s make our world a healthier place. Your feedback is welcomed!

Rob

Chief Science Officer


Dr. Rob Gussenhoven is a recognized expert and thought leader in the treatment of pain and the understanding of pain processes. Follow him on Twitter at @RobG_PharmD.

 

The Chemical Castration of America

shutterstock_281349731-edited

Well, at least for those taking opioids.

On the list of things that can be done to help achieve improving outcomes and reducing costs, possibly the lowest hanging fruit is in improving the current treatment of acute and chronic pain. This starts with understanding the pros and cons of opiate use.

The opioid conundrum, as termed by the Institute Of Medicine (IOM), reveals that patients who are receiving opiates seldom recover. The opioid conundrum is a major contributor to the healthcare burden. One of Theradym’s goals is to provide the evidence needed to enable treatment algorithms defining the best use of opiates for acute and chronic pain.

Society is preoccupied with opiate addiction and abuse issues. What is not being recognized is that recovery is being inhibited by two major side effects of opiate therapy, both of which have been known for over a century. They are 1) opiate induced magnification of pain (hyperalgesia) and 2) suppression of hormones (endocrinopathy). We are working to define how this suppression of hormone production is preventing adequate patient management.

Studies have shown that morphine induces a dramatic, long-lasting decrease in testosterone production in men and women, which persists during prolonged opiate therapy. This effect can occur after a few hours, with testosterone concentrations reaching castration levels (< 1ng/mL). (Read the article in Pain Physician Journal)

There’s no doubt about it: Opiates play a critical role in treating acute pain. Our memory of pain defines our future perception of pain and poorly managed acute pain can lead to chronic pain syndromes. So, opiates have an important role to play. However, using opiates properly requires a greater understanding of the long-term impacts of prolonged opiate use on recovery.

We need to know, for instance, that the use of opiates for as little as a couple of weeks can contribute to additional pathologies and disease states. These additional health issues are a broad mix that run from osteoporosis and metabolic syndrome to depression. Unfortunately, these illnesses are seldom recognized as being produced or magnified by the downstream effects of opiate use.

We are committed to exploring and developing complementary therapies and treatment algorithms that will limit or mitigate opiate use. This will result in improved patient outcomes and reduced medical resource utilization. A lot of effort has been made to provide the tools needed and to develop competencies with primary care physicians that enable safer long-term opiate use. Why not define the best way to recover and limit opiate use to a couple of weeks? When we do, the abuse and addiction liabilities will no longer be the problems they currently are.

Rob


 

Dr. Rob Gussenhoven is recognized as an expert and thought leader on the treatment of pain and the understanding of pain processes. Follow him on Twitter at RobG_PharmD.